A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced lung cancer and determine the recommended dose for subsequent studies.

Trial Details

NCT ID
NCT07381829
Phase
PHASE1
Sponsor
HC Biopharma Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HC010
  • Paclitaxel (Chemotherapy)
  • Pemetrexed
  • Etoposide
  • Carboplatin/Cisplatin
  • Docetaxel
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • 1\. Fully understand this trial and voluntarily sign the informed consent form.
  • 2\. For locally recurrent or metastatic non-resectable advanced solid tumors that are diagnosed by histological or cytopathological pathology and c…
  • 3\. At least one measurable lesion according to RECIST v1.1 (patients with only brain lesion as target lesion are not accepted).
  • 4\. Eastern Cancer Assistance Group (ECOG) in the United States had a performance score of 0 or 1 and did not worsen within 2 weeks prior to the fi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →